Clinical Trials Logo
  1. Home
  2. Giant Cell Tumor of Bone
  3. NCT04586660

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Giant Cell Tumor of Bone Clinical Trial

Official title:
An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Clinical Trial Summary

The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04586660
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email medinfo@amgen.com
Status Recruiting
Phase Phase 4
Start date August 17, 2023
Completion date October 16, 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Active, not recruiting NCT04255576 - Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone Phase 1/Phase 2
Completed NCT03301857 - Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Phase 4
Completed NCT05402865 - A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
Recruiting NCT03295981 - Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone Phase 3
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT03259152 - Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone Phase 3
Recruiting NCT05595603 - Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage Phase 2
Not yet recruiting NCT03358212 - Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China N/A
Completed NCT04002817 - Giant Cell Tumor of the Bone in Young Patients
Completed NCT00396279 - Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone Phase 2
Terminated NCT00889590 - Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Phase 2
Active, not recruiting NCT03449108 - LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Phase 2
Not yet recruiting NCT05813665 - A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Phase 3
Completed NCT02996734 - Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment N/A